Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Shares in CytRx Corporation Are Surging Higher

By Todd Campbell - May 4, 2015 at 12:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CytRx Corporation announced positive early-stage trial data for aldoxorubicin.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares in CytRx Corporation (NASDAQ: CYTR) are rallying by more than 30% after the company released interim positive results for aldoxorubicin in chemotherapy resistant cancer.

So What: CytRx Corporation is a clinical stage biotech company that is developing a second generation variation of the cancer drug doxorubicin, called aldoxorubicin.

The company's most advanced clinical trials for aldoxorubicin are evaluating the drug in soft tissue sarcoma, a rare cancer that develops in bone and muscle tissue. Previously-released data for use in soft tissue sarcoma patients is encouraging, with patients taking the drug seeing a two-fold improvement in survival versus doxorubicin.

Today's report updates investors on aldoxorubicin's potential use alongside the chemotherapy drugs gemcitabine or ifosfamide. In phase 1b studies, patients receiving aldoxorubicin combination therapy saw tumor shrinkage after just two cycles. One bone cancer patient saw a complete tumor response after five cycles.

Now What: CytRx Corporation's aldoxorubicin is intriguing because although doxorubicin is a standard treatment, its dosing is restricted by its side effects and its potential to damage heart tissue. By pairing up a novel single molecule with doxorubicin, aldoxorubicin improves doxorubicin's safety profile, allowing it to be dosed at far higher levels that appear to improve efficacy.

If aldoxorubicin can continue to outperform doxorubicin in trials, including in combination trials alongside other commonly-used cancer treatments, it could displace doxorubicin use altogether. Granted, there are a lot of risks that could derail aldoxorubicin in trials, particularly as it's used in more patients, but its effectiveness so far suggests that risk tolerant investors may want to keep CytRx Corporation on their watch list. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.